VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial

Authors :: M.R. Mirza
X. Wu
J. Zhu
R. Yin
J. Yang
J. Liu
J. Wang
L. Wu
Z. Liu
Y. Gao
D. Wang
G. Lou
H. Yang
Q. Zhou
B. Kong
Y. Huang
L. Chen
X. Zhen
J. Dong
J. Hou
Source :: Annals of Oncology. 34:124-125
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools